Sarepta Therapeutics Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Scroll to see more
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Valuation Ratios
P/E Ratio49.37
Forward P/E15.47
P/S Ratio6.117.2512.1911.1724.91
P/B Ratio7.6010.5029.558.4517.66
Price/Tangible Book7.7410.8730.148.5817.98
Price/FCF532.53
Price/OCF125.19
Enterprise Value Ratios
EV/Revenue6.226.9811.6910.5723.00
EV/EBITDA46.25
EV/EBIT54.25
EV/FCF491.69
Profitability & Returns
Return on Equity (ROE)0.20%-0.86%-1.07%-0.50%-0.70%
Return on Assets (ROA)0.04%-0.05%-0.11%-0.09%-0.15%
Return on Invested Capital (ROIC)0.19%-0.93%-3.54%
Return on Capital Employed (ROCE)0.07%-0.10%-0.21%-0.17%-0.22%
Leverage & Solvency Ratios
Debt/Equity0.881.604.201.231.41
Debt/EBITDA3.74
Debt/FCF42.47
Liquidity Ratios
Current Ratio4.203.954.135.755.97
Quick Ratio2.743.233.635.054.99
Efficiency Ratios
Asset Turnover0.530.390.300.230.23
Inventory Turnover2.103.905.214.123.90
Yield & Distribution Ratios
Earnings Yield0.02%-0.06%-0.06%-0.05%-0.04%
FCF Yield-0.03%-0.06%-0.03%-0.06%0.00%
Buyback Yield-0.17%-0.06%-0.08%-0.04%-0.06%